Compare ALLT & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALLT | DNA |
|---|---|---|
| Founded | 1996 | 2008 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 506.5M | 562.3M |
| IPO Year | 2006 | N/A |
| Metric | ALLT | DNA |
|---|---|---|
| Price | $10.30 | $9.67 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 2 |
| Target Price | ★ $13.25 | $10.50 |
| AVG Volume (30 Days) | 417.4K | ★ 870.2K |
| Earning Date | 02-24-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | $98,512,000.00 | ★ $180,606,000.00 |
| Revenue This Year | $12.08 | N/A |
| Revenue Next Year | $12.38 | $3.07 |
| P/E Ratio | $478.96 | ★ N/A |
| Revenue Growth | ★ 7.51 | N/A |
| 52 Week Low | $4.37 | $5.00 |
| 52 Week High | $11.92 | $17.58 |
| Indicator | ALLT | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 52.26 | 56.20 |
| Support Level | $10.70 | $8.82 |
| Resistance Level | $11.04 | $10.42 |
| Average True Range (ATR) | 0.59 | 0.53 |
| MACD | -0.05 | 0.09 |
| Stochastic Oscillator | 39.46 | 70.51 |
Allot Ltd is a provider of network intelligence and security solutions for service providers and enterprises. The company's solutions are deployed globally for network and application analytics, traffic control and shaping, and network-based security services. The firm's multi-service platforms are deployed by mobile, fixed, and cloud service providers and enterprises. The company has a customer base in Europe, Asia and Oceania, the Americas, the Middle East, and Africa.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.